| For: | Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14(21): 3416-3420 [PMID: 18528940 DOI: 10.3748/wjg.14.3416] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v14/i21/3416.htm |
| Number | Citing Articles |
| 1 |
N. H. Nguyen, P. VuTien, R. T. Garcia, H. Trinh, H. Nguyen, K. Nguyen, B. Levitt, M. H. Nguyen. Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6. Journal of Viral Hepatitis 2010; 17(10) doi: 10.1111/j.1365-2893.2009.01226.x
|
| 2 |
Giuseppe Indolfi, Giusi Mangone, Elisa Bartolini, Gabriella Nebbia, Pier Luigi Calvo, Maria Moriondo, Pier-Angelo Tovo, Maurizio de Martino, Chiara Azzari, Massimo Resti, David R. Booth. Comparative Analysis of rs12979860 SNP of the IFNL3 Gene in Children with Hepatitis C and Ethnic Matched Controls Using 1000 Genomes Project Data. PLoS ONE 2014; 9(1) doi: 10.1371/journal.pone.0085899
|
| 3 |
Juntao Liu, Ruoyan Liu, Jingfei Huang, Qing Liu, Jiarun Cui, Huimei Yu. Capillaria hepatica—A Neglected Zoonotic Parasite. Veterinary Sciences 2026; 13(1) doi: 10.3390/vetsci13010100
|
| 4 |
Xiang-Wei Liao, Yun Ling, Xin-Hua Li, Yue Han, Shen-Ying Zhang, Lei-Lei Gu, De-Ming Yu, Bi-Lian Yao, Dong-Hua Zhang, Gen-Di Jin, Zhi-Meng Lu, Qi-Ming Gong, Xin-Xin Zhang. Association of Genetic Variation in Il28B with Hepatitis C Treatment-Induced Viral Clearance in the Chinese Han Population. Antiviral Therapy 2011; 16(2) doi: 10.3851/IMP1703
|
| 5 |
Gautam Ray. Factors affecting outcome of treatment of chronic hepatitis C: result of an open label study from eastern India. Tropical Doctor 2016; 46(1) doi: 10.1177/0049475515569519
|
| 6 |
Muhammad Imran, Sobia Manzoor, Sikandar Azam, Saleha Resham. Genetic variant of IL28B rs12979860, as predictive marker of interferon‐based therapy in Pakistani population. APMIS 2015; 123(4) doi: 10.1111/apm.12365
|
| 7 |
K. Muller, A. Rodgers, R. Wundke, V. Waddell, R. Altus, D. L. Gordon, A. Wigg. Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward. Internal Medicine Journal 2012; 42(7) doi: 10.1111/j.1445-5994.2012.02798.x
|
| 8 |
Philip Vutien, Nghia H Nguyen, Huy N Trinh, Jiayi Li, Ruel T Garcia, Gabriel Garcia, Khanh K Nguyen, Huy A Nguyen, Brian S Levitt, Emmet B Keeffe, Mindie H Nguyen. Similar Treatment Response to Peginterferon and Ribavirin in Asian and Caucasian Patients With Chronic Hepatitis C. American Journal of Gastroenterology 2010; 105(5) doi: 10.1038/ajg.2009.635
|
| 9 |
Huy Anh Tran, Glenn Edward Malcolm Reeves, Robert Gibson, John Richard Attia. Development of thyroid diseases in the treatment of chronic hepatitis C with α‐interferon may be a good prognosticator in achieving a sustained virological response: A meta‐analysis. Journal of Gastroenterology and Hepatology 2009; 24(7) doi: 10.1111/j.1440-1746.2009.05874.x
|
| 10 |
Jacinta A Holmes, William Sievert, Alexander J Thompson.
IL28B
Polymorphism and Genetic Biomarkers of Viral Clearance in Hepatitis C Virus Infection
. Biomarkers in Medicine 2011; 5(4) doi: 10.2217/bmm.11.47
|
| 11 |
Kenneth Kar-Lung Yan, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan. Rate and Factors Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary Referral Hospital. Digestive Diseases and Sciences 2010; 55(12) doi: 10.1007/s10620-010-1412-1
|
| 12 |
Huy A Tran, Tracey L Jones, Robert Gibson, Glenn EM Reeves. Thyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study. BMC Endocrine Disorders 2011; 11(1) doi: 10.1186/1472-6823-11-10
|
| 13 |
Siddapuram Sivaprasad, Padaki Nagaraja Rao, Rajesh Gupta, Kaitha Ashwini, Duvvuru Nageshwar Reddy. The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India. Journal of Clinical and Experimental Hepatology 2012; 2(2) doi: 10.1016/S0973-6883(12)60098-X
|
| 14 |
Hu Li, Jia-Li Tan, Jian-Rui Li, Nan-Nan Liu, Jin-Hua Chen, Xiao-Qin Lv, Li-li Zou, Biao Dong, Zong-Gen Peng, Jian-Dong Jiang. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. Biomedicine & Pharmacotherapy 2019; 116 doi: 10.1016/j.biopha.2019.108976
|
| 15 |
Deepinder Kaur, Rajoo Singh Chhina, Omesh Goyal, Prerna Goyal. Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India. Journal of Gastrointestinal Infections 2015; 5(1) doi: 10.5005/jp-jogi-5-1-24
|
| 16 |
Alip Ghosh, Sara Romani, Shyam Kottilil, Bhawna Poonia. Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal. International Journal of Molecular Sciences 2020; 21(20) doi: 10.3390/ijms21207473
|
| 17 |
Mario Frias, Antonio Rivero-Juárez, Pedro López-López, Antonio Rivero. Pharmacogenetics and the Treatment of HIV-/HCV-Coinfected Patients. Pharmacogenomics 2018; 19(12) doi: 10.2217/pgs-2018-0046
|
| 18 |
Christine Y. Chang, Pauline Nguyen, An Le, Changqing Zhao, Aijaz Ahmed, Tami Daugherty, Gabriel Garcia, Glen Lutchman, Radhika Kumari, Mindie H. Nguyen. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 2017; 96(6) doi: 10.1097/MD.0000000000006128
|
| 19 |
Thomas Urban, Michael R. Charlton, David B. Goldstein. Introduction to the genetics and biology of interleukin-28B. Hepatology 2012; 56(1) doi: 10.1002/hep.25794
|
| 20 |
Albert Friedrich Stättermayer, Rudolf Stauber, Harald Hofer, Karoline Rutter, Sandra Beinhardt, Thomas Matthias Scherzer, Kerstin Zinober, Christian Datz, Andreas Maieron, Emina Dulic–Lakovic, Harald H. Kessler, Petra Steindl–Munda, Michael Strasser, Christoph Krall, Peter Ferenci. Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology 2011; 9(4) doi: 10.1016/j.cgh.2010.07.019
|
| 21 |
Sabela Lens García, Mairene Coto-Llerena, Sofía Pérez del Pulgar Gallart, Xavier Forns Bernhardt. Genética y tratamiento de la hepatitis C: ¿hacia un tratamiento personalizado?. Gastroenterología y Hepatología 2011; 34(5) doi: 10.1016/j.gastrohep.2010.12.008
|
| 22 |
Paul J Clark, Alex J Thompson, John G McHutchison. IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies. American Journal of Gastroenterology 2011; 106(1) doi: 10.1038/ajg.2010.370
|
| 23 |
Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Yung Sang Lee, Kang Mo Kim, Kwan Soo Byun, Kwang-Hyub Han, Kwan Sik Lee, Seung Woon Paik, Seung Kew Yoon, Dong Jin Suh. High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clinical and Molecular Hepatology 2013; 19(1) doi: 10.3350/cmh.2013.19.1.60
|
| 24 |
Kasem Kulkeaw, Worakamol Pengsart. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachines 2021; 12(7) doi: 10.3390/mi12070842
|
| 25 |
Arghavan Haj-sheykholeslami, Maryam Keshvari, Heidar Sharafi, Ali Pouryasin, Khalil Hemmati, Fatemeh Mohammadzadehparjikolaei. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World Journal of Gastroenterology 2015; 21(29): 8935-8942 doi: 10.3748/wjg.v21.i29.8935
|
| 26 |
Mahtab Daneshvar, Mehri Nikbin, Solmaz Talebi, Foozieh Javadi, Mohammad Reza Aghasadeghi, Sanaz Mahmazi, Seyed Mehdi Sadat. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iranian Red Crescent Medical Journal 2016; 18(9) doi: 10.5812/ircmj.28566
|
| 27 |
L. H. Nguyen, M. H. Nguyen. Systematic review: Asian patients with chronic hepatitis C infection. Alimentary Pharmacology & Therapeutics 2013; 37(10) doi: 10.1111/apt.12300
|
| 28 |
BYM Soh, R Kumar, VSM Ekstrom, CYH Lin, S Thangaraju, HH Tan, KP Chan, LHL Choong, D Teo, WC Chow. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Medical Journal 2019; 60(1) doi: 10.11622/smedj.2018078
|
| 29 |
Dongliang Ge, Jacques Fellay, Alexander J. Thompson, Jason S. Simon, Kevin V. Shianna, Thomas J. Urban, Erin L. Heinzen, Ping Qiu, Arthur H. Bertelsen, Andrew J. Muir, Mark Sulkowski, John G. McHutchison, David B. Goldstein. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262) doi: 10.1038/nature08309
|
| 30 |
Dong-Won Kim, Seoung-Ae Lee, Hong Kim, You-Sub Won, Bum-Joon Kim, Jason Blackard. Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Naïve Korean Patients Chronically Infected with HCV Genotype 1b. PLoS ONE 2014; 9(1) doi: 10.1371/journal.pone.0087773
|
| 31 |
LI-SHENG WU, HONG WANG, XIAO-PING GENG. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Experimental and Therapeutic Medicine 2012; 3(2) doi: 10.3892/etm.2011.385
|
| 32 |
Ajit Sood, Vandana Midha, Omesh Goyal, Syed Hissar, Suresh Kumar Sharma, Pankaj Khanna. Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in treatment-naïve ‘real-life’ patients in India. Indian Journal of Gastroenterology 2014; 33(4) doi: 10.1007/s12664-014-0451-5
|
| 33 |
Ashwin Balagopal, David L. Thomas, Chloe L. Thio. IL28B and the Control of Hepatitis C Virus Infection. Gastroenterology 2010; 139(6) doi: 10.1053/j.gastro.2010.10.004
|
| 34 |
Lourianne N. Cavalcante, Kiyoko Abe‐Sandes, Ana Luiza D. Angelo, Taisa M. B. Machado, Denise C. Lemaire, Carlos M. C. Mendes, João R. Pinho, Fernanda Malta, Luiz G.C. Lyra, André C. Lyra. IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population. Liver International 2012; 32(3) doi: 10.1111/j.1478-3231.2011.02653.x
|
| 35 |
Xiao-Xiao Wang, Bi-Fen Luo, Han-Ji Jiang, Xu Cong, Qian Jin, Dan-Li Ma, Lai Wei, Bo Feng. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. World Journal of Gastroenterology 2018; 24(40): 4554-4564 doi: 10.3748/wjg.v24.i40.4554
|
| 36 |
Victoria A. Sublette, Mark W. Douglas, Kirsten McCaffery, Jacob George, Kathryn Nicholson Perry. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. Liver International 2013; 33(6) doi: 10.1111/liv.12138
|
| 37 |
Wangxia Tong, Jianyun Zhu, Ning Luo, Xiaohua Yang, Zhiying Lei, Xiaoliang Huang, Zhixin Zhao, Xiaohong Zhang, Zhiliang Gao, Zhonghua Jiang. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. Gastroenterology Research and Practice 2016; 2016 doi: 10.1155/2016/5397407
|